Food and Drug Administration

Dermatologic and Ophthalmic Drugs Advisory Committee

September 9, 2003



The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Evaluating A Systemic Therapy Psoriasis, Dr. Stern (HTM) (PPT)

Raptiva™ (efalizumab) Introduction, Dr. Michelle Rohrer, PhD, Genentech, Inc. (HTM) (PPT)

Raptiva™ (efalizumab) Plaque Psoriasis: The Unmet Need, Dr. Mark Lebwohl, MD, Mount Sinai School of Medicine (HTM) (PPT)

Efalizumab Mechanism of Action and Dose Determination, Charles Johnson, MB, ChB, Genentech, Inc. (HTM) (PPT)

Raptiva™ (efalizumab) Efficacy, Dr. Lee Kaiser, PhD, Genentech, Inc. (HTM) (PPT)

Raptiva™ (efalizumab) Safety, Dr. Richard Chin, MD, Genentech, Inc. (HTM) (PPT)

Raptiva™ (efalizumab) Benefit: Risk Assessment, Charles Johnson, MB, ChB, Genentech, Inc. (HTM) (PPT)

Biologic License Application STN BL 125075/0: Efalizumab for the Treatment of Chronic Plaque Psoriasis, FDA (HTM) (PPT)